Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (49)	6/1/2000 12:50:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 139

Huh? To make a long story short, its GMK vaccine failed ... (Nadine Wong is editor and publisher of the BioTech Navigator Newsletter) biz.yahoo.com It was known when the Phase III trial started that GMK therapy requires the body to develop an immune response to the vaccine. The onset of clinical effect for a vaccine appears later than that of other cancer therapies which are given in high doses over a much shorter period of time. From what we know, the relapse-free and overall survival rates for the GMK vaccine in the Phase III trial are tracking generally as expected at this time based on our previous clinical experience. http://biz.yahoo.com/prnews/000526/ny_progeni.html (Alan N. Houghton, M.D. is Chairman of Progenics' Cancer Scientific Advisory Board, Chairman, Immunology Program, Memorial Sloan-Kettering Cancer Center and Professor, Cornell University Medical Center in New York City.) Well I bought some the other day, and I see no need to "wait on the sidelines" with Nadine.

To: Jim Oravetz who wrote (49)	1/9/2001 1:02:33 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 139

Progenics: Report Shows Promise For PRO 140 HIV Drug Dow Jones Newswires TARRYTOWN, N.Y. -- Progenics Pharmaceuticals Inc.'s (PGNX) HIV inhibitor PRO 140 demonstrated "broad and potent" antiviral activity in preclinical models of HIV infection. In a press release Tuesday, the biopharmaceutical company said PRO 140, an monoclonal antibody, targets CCR5, a protein that is a co-receptor for HIV entry and infection. CCR5, which under normal conditions activates certain immune system cells, is found on the surface of cell targeted by HIV. Progenics agreed to collaborate with Protein Design Labs Inc. (PDLI) to develop a humanized PRO 140 antibody. Shares of the company recently traded at $15.81, up $1.44 or 10%, on Nasdaq volume of 5,800 shares. Average volume is 67,427 shares. Company Web site: progenics.com